Nitric Acid

Nitric Acid

SCHEMBL813725

CCCNCCC.O=[N+]([O-])O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
PAOX Q6QHF9 1/20 0.43
TSHR P16473 2/20 0.38
ADH1B P00325 1/20 0.38
ADH1A P07327 1/20 0.38
ADH7 P40394 1/20 0.38
ALDH1A1 P00352 3/20 0.36
ANPEP P15144 1/20 0.35
HCAR3 P49019 1/20 0.33
CA1 P00915 1/20 0.32
S1PR2 O95136 5/20 0.31
S1PR4 O95977 5/20 0.31
S1PR1 P21453 5/20 0.31
S1PR3 Q99500 5/20 0.31
S1PR5 Q9H228 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP9 P14780 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitric Acid SCHEMBL30555522 0.91 PAOX (0.38) CA5ACA5BPAOXTSHRADH1B
Nitric Acid SCHEMBL7567345 0.84 ALDH1A1 (0.50) CA5ACA5BPAOXTSHRADH1B
Dipentylamine SCHEMBL7568173 0.82 ALDH1A1 (0.62) PAOXTSHRADH1BADH1AADH7
Nitric Acid SCHEMBL8193567 0.81
Dipentylamine SCHEMBL3469134 0.80 ALDH1A1 (0.59) PAOXTSHRADH1BADH1AADH7
Nitric Acid SCHEMBL7562827 0.80 ALDH1A1 (0.59) PAOXTSHRADH1BADH1AADH7
Nitric Acid SCHEMBL6390465 0.80 ALDH1A1 (0.59) PAOXTSHRADH1BADH1AADH7
Nitric Acid SCHEMBL6392617 0.80 ALDH1A1 (0.59) PAOXTSHRADH1BADH1AADH7
Nitric Acid SCHEMBL7562435 0.80 ALDH1A1 (0.59) PAOXTSHRADH1BADH1AADH7
Nitric Acid SCHEMBL7567094 0.80 ALDH1A1 (0.59) PAOXTSHRADH1BADH1AADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7658872-B2 Process for preparing semipermeable membranes having improved permeability GE OSMONICS, INC. (US) 2010-02-09 US claimed
CN-100339153-C Process for preparing semipermeable membranes having improved permeability GE OSMONICS INC (US) 2007-09-26 CN claimed
CN-1646203-A Process for preparing semipermeable membranes having improved permeability GE OSMONICS INC (US) 2005-07-27 CN claimed
US-20050103705-A1 Process for preparing semipermeable membranes having improved permeability GE OSMONICS, INC. 2005-05-19 US claimed
EP-1483033-A4 A PROCESS FOR PREPARING SEMIPERMEABLE MEMBRANES HAVING IMPROVED PERMEABILITY OSMONICS INC (US) 2005-04-13 EP claimed
EP-1483033-A1 A PROCESS FOR PREPARING SEMIPERMEABLE MEMBRANES HAVING IMPROVED PERMEABILITY OSMONICS, INC. (US) 2004-12-08 EP claimed
WO-2003074152-A1 A PROCESS FOR PREPARING SEMIPERMEABLE MEMBRANES HAVING IMPROVED PERMEABILITY GE OSMONICS, INC. (US) 2003-09-12 WO claimed
US-20020016505-A1 Heat storage material having solid/solid phase transition remains solid through application; heat resistance; materials handling MERCK PATENT GMBH (DE) 2002-02-07 US claimed
CN-1321720-A Storage medium of latent heat storage system MERCK PATENT GMBH (DE) 2001-11-14 CN claimed
EP-1148108-A1 Storage media for latent heat storage units MERCK PATENT GmbH (DE) 2001-10-24 EP claimed
CN-105189531-B Peptides for skin rejuvenation and methods of use thereof 安特易斯有限公司 2020-02-21 CN disclosed
WO-2020022503-A1 NON-COVALENT NANOCARBON-POLYMER HYBRID COMPOSITION 国立大学法人名古屋大学 2020-01-30 WO disclosed
EP-2743262-B1 Method for Obtaining a Triazine Compound with at least one Tertiary Amino Group BOREALIS AGROLINZ MELAMINE (AT) 2016-04-27 EP disclosed
US-9314743-B2 Residential reverse osmosis system PENTAIR RESIDENTIAL FILTRATION, LLC (US) 2016-04-19 US disclosed
CN-105189531-A Peptides for skin rejuvenation and methods of using the same NEOCUTIS SA 2015-12-23 CN disclosed
CN-1329361-A Application of phase transformation material in radiator for electronic element and device MERCK PATENT GMBH (DE) 2002-01-02 CN disclosed
EP-1162659-A2 Use of PCM in heat sinks for electronic devices MERCK PATENT GmbH (DE) 2001-12-12 EP disclosed
CN-1321720-A Storage medium of latent heat storage system MERCK PATENT GMBH (DE) 2001-11-14 CN disclosed
EP-1148108-A1 Storage media for latent heat storage units MERCK PATENT GmbH (DE) 2001-10-24 EP disclosed
US-4370402-A Dye reducing composition for dye transfers, photographic transparencies and color prints ANDERSON HARRY 1983-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016505-A1 Heat storage material having solid/solid phase transition remains solid through application; heat resistance; materials handling HSPH1, HSP90AA1, HSPA1A CA5A 3019/4885CA5B 3016/4885PAOX 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.